Concepedia

Ali Tafreshi

AT

57

Publications

24.3K

Citations

32

H-Index

2006

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California San Diego

Wollongong Hospital

Royal Marsden Hospital

Hospital Universitario Insular de Gran Canaria

Ali Tafreshi is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, cancer therapeutics, and oncology.

ORCID

Top concepts

Publications per year

2006–2023

57

Publications

57

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 9.8K citations · Full text

Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning

Daniel Kermany, Michael H. Goldbaum, Wenjia Cai et al. · Cell · 2018 · 4.5K citations · Full text

, , +11

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Alexander Luft, David Vicente et al. · New England Journal of Medicine · 2018 · 3.5K citations · Full text

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · Journal of Clinical Oncology · 2019 · 1.6K citations

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · Journal of Clinical Oncology · 2021 · 1K citations · Full text

Rows per page

1–5 of 57